Evidence map›Paper›PMID 31861475›Full record

ArticleMedicina (Kaunas, Lithuania)2019

Inhibition of MELK Protooncogene as an Innovative Treatment for Intrahepatic Cholangiocarcinoma.

Antonio Cigliano, Maria Giulia Pilo, Marta Mela, Silvia Ribback, Frank Dombrowski, Giovanni Mario Pes, Antonio Cossu, Matthias Evert, Diego Francesco Calvisi, Kirsten Utpatel

Open access · goldAbstract read
In one paragraph

Article in Medicina (Kaunas, Lithuania), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Antonio CiglianoInstitut für Pathologie, Universitätsklinikum Regensburg, 93053 Regensburg, Germany.
Maria Giulia PiloInstitut für Pathologie, Universitätsmedizin Greifswald, 17475 Greifswald, Germany.
Marta MelaInstitut für Pathologie, Universitätsmedizin Greifswald, 17475 Greifswald, Germany.
Silvia RibbackInstitut für Pathologie, Universitätsmedizin Greifswald, 17475 Greifswald, Germany.
Frank DombrowskiInstitut für Pathologie, Universitätsmedizin Greifswald, 17475 Greifswald, Germany.
Giovanni Mario PesDepartment of Clinical, Surgical, Experimental Sciences, University of Sassari, 07100 Sassari, Italy.
Antonio CossuDepartment of Clinical, Surgical, Experimental Sciences, University of Sassari, 07100 Sassari, Italy.
Matthias EvertInstitut für Pathologie, Universitätsklinikum Regensburg, 93053 Regensburg, Germany.
Diego Francesco CalvisiInstitut für Pathologie, Universitätsklinikum Regensburg, 93053 Regensburg, Germany.
Kirsten UtpatelInstitut für Pathologie, Universitätsklinikum Regensburg, 93053 Regensburg, Germany.
Universitätsmedizin Greifswald · DEUniversity Hospital Regensburg · DEUniversity of Sassari · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AgedAnimalsCell ProliferationCholangiocarcinomaEnhancer of Zeste Homolog 2 ProteinFemaleForkhead Box Protein M1HumansImmunochemistryLiverMaleMiddle AgedProtein Serine-Threonine KinasesRabbitsReal-Time Polymerase Chain ReactionEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanForkhead Box Protein M1FOXM1 protein, humanMELK protein, humanProtein Serine-Threonine KinasesEZH2FOXM1intrahepatic cholangiocarcinomaMELKtargeted therapies

Identifiers

PMID31861475
PMCPMC7023300
OpenAlexW2996177965

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.